Jump to content

New drug trial starting up!!!


Recommended Posts

Cellectar gets FDA approval for clinical trials

State Journal staff

Cellectar, a Madison company developing small molecules to light up tumors and shrink them, has received approval from the U.S. Food and Drug Administration to begin studies in patients this year, the company announced Tuesday.

Two phase 1 studies at four medical centers will evaluate appropriate doses of CLR 1404, which is designed for patients with advanced solid-tumor cancers. The studies are expected to begin by June, Cellectar said.

Jamey Weichert, a UW-Madison chemist and co-founder of Cellectar, has said the drug could help patients with lung, prostate and pancreatic cancers.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.